-
Mashup Score: 0
We write this editorial some 2.5 years after the first national COVID-19 lockdown was announced in the UK on 17 March 2020. We reflect on the reality of how the pandemic and the national response to the pandemic affected a cancer care system that was already under severe strain.[1][1] In their
Source: BMJ OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Sex-sensitive and gender-sensitive medicine is a novel field that explores the impact of sex and gender on health and disease. Sex is defined by biological features such as genetic, hormonal, anatomical and physiological characteristics.[1][1] Gender is a multidimensional attribute enacted in human
Source: BMJ OncologyCategories: Healthcare Professionals, Latest HeadlinesTweet-
Inclusive oncological trials and targeted treatments cannot ignore sex and gender #some4surgery #BMJ #Oncology #gender https://t.co/yDA09rLma4
-
-
Mashup Score: 0Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study - 11 month(s) ago
Objective To assess time trends in the inclusion of health-related quality of life (QoL) among study endpoints and in the reporting of QoL results in study publications, randomised phase III oncology trials published between 2017 and 2021 were compared with the trials published in the previous 5 years. Methods and analysis All issues published between 2012 and 2021 by 11 major journals were…
Source: BMJ OncologyCategories: Latest Headlines, Oncologists2Tweet-
Time trends in health-related quality of life assessment and reporting within publications - still too much unpublished collected data and failure to include in primary publications #PRO #QoL https://t.co/mcOlQTJvig
-
-
Mashup Score: 0
The majority of the initial seminal cancer treatment trials during the 1970s and later on focused on clinical efficacy and clinician-assessed harms. Patient-reported outcome measures (PROMs) including health-related quality of life (QoL) were rarely collected. Even once they started to be
Source: BMJ OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Modern cancer trials still lack information about QoL impacts on patients https://t.co/dUEp9WIK6O via @UCLHresearch 's #AllanHackshaw
-
-
Mashup Score: 0Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps - 12 month(s) ago
Long-term screening with serum prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to unacceptable overdiagnosis. Over the past decade, diagnostic methods have improved and the indolent nature of low-grade prostate cancer has been established. These advances now enable more selective detection of potentially lethal prostate cancer. This…
Source: BMJ OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps https://t.co/LqPZU48DKT via @auvinen_anssi et al @susan_bewley @MichaelBaum11 @petersasieni @paulpharoah @dr_coops @paula_span @SteveLaitner @DrREWeaver
-
COVID-19 and cancer in the UK: which will prove to be the lesser of two evils? https://t.co/JK6wOOTgJi via @SullivanProf et al